| Patient | Josephine Baker |
|---|---|
| Date of birth | 1906-06-03 |
| Identifiers | MRN HR-ML049-SYN-TD; SSN (made up) 000-49-3172 |
| Document date | 1969-07-21 |
| Author | Colette Ashby-Nwosu, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Twelve-week review: exercise test, lipids, mood and the return to performing. [S]
Ms. Baker returns about four months after the heart attack and five weeks after her sick visit for a nosebleed, which has not recurred. She completed all 36 cardiac rehabilitation sessions last week. On the treadmill test today she walked for nine minutes without chest pain or breathlessness. She has been practicing songs and dance steps at home for up to an hour, and she has an offer for a short run of concerts in the autumn. Her home blood pressure averages 122/74. She is sleeping well, her mood is better, and the rehabilitation psychologist helped her with the worry about her family and her debts. She has taken every dose of her medicines. [S]
| Element | Detail |
|---|---|
| Rehabilitation | All 36 sessions completed |
| Exercise test | Nine minutes, about 10 METs, no angina, no ischemic change |
| Home blood pressure | Average 122/74 mmHg |
| Mood | PHQ-9 3, from 7 |
| Plans | A short run of concerts in the autumn |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations or lightheadedness, including during the test |
| Respiratory | Negative | No breathlessness |
| Ears, nose, mouth, and throat | Negative | No further nosebleeds |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
| Psychiatric | Negative | Mood better; sleeping well |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet daily | Oral route | 1969-03-24 | active | S |
| Ticagrelor 90 mg oral tablet, one tablet twice daily | One tablet twice daily | Oral route | 1969-03-24 to 1969-04-28 | completed | S |
| Clopidogrel 75 mg oral tablet: a 600 mg loading dose (eight tablets) 24 hours after the last ticagrelor, then one tablet daily | One tablet daily after a 600 mg loading dose | Oral route | 1969-04-28 | active | S |
| Atorvastatin 80 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1969-03-24 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet daily | One tablet daily | Oral route | 1969-03-24 | active | S |
| Lisinopril 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1969-03-24 to 1969-04-28 | completed | S |
| Lisinopril 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1969-04-28 | active | S |
| Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if the pain is not better 5 minutes after the first tablet | One tablet under the tongue every 5 minutes as needed for chest pain, up to 3 doses | Sublingual route | 1969-03-24 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1969-07-21 | Body height | 168 | cm | S |
| 1969-07-21 | Body weight | 60.4 | kg | S |
| 1969-07-21 | Body mass index (BMI) [Ratio] | 21.4 | kg/m2 | S |
| 1969-07-21 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1969-07-21 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1969-07-21 | Heart rate | 58 | /min | S |
| 1969-07-21 | Respiratory rate | 14 | /min | S |
| 1969-07-21 | Body temperature | 36.5 | Cel | S |
| 1969-07-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1969-07-21 | Cholesterol [Mass/volume] in Serum or Plasma | 128 | mg/dL | <=199 mg/dL | Normal | S |
| 1969-07-21 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 62 | mg/dL | Secondary-prevention goal below 70 mg/dL | Normal | S |
| 1969-07-21 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 | mg/dL | >=50 mg/dL | Normal | S |
| 1969-07-21 | Triglyceride [Mass/volume] in Serum or Plasma | 72 | mg/dL | <=149 mg/dL | Normal | S |
| 1969-07-21 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 7-35 U/L | Normal | S |
| 1969-07-21 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 1969-07-21 | Overall summary score [SAQ] | 94 | {score} | S |
Vital signs recorded on 1969-07-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well and energetic; blood pressure 122/76, pulse 58; weight 60.4 kg |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear |
| Nose | Left nasal septum healed |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Breathlessness on exertion and tiredness since discharge three weeks after the heart attack, without chest pain at rest; cause to be determined (heart function, ischemia, anemia, medicine effect or deconditioning) | resolved | confirmed | R06.09 | S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology attributed it to ticagrelor. |
| Coronary artery disease after a non-ST-elevation myocardial infarction three weeks before intake, treated with one drug-eluting stent to the right coronary artery; synthetic modern episode linked to the documented heart attack of March 1912 | active | confirmed | I25.10 | S — Synthetic modern diagnosis; the 1969 heart attack remains D in the history. |
| High blood pressure, found during the hospital stay for the heart attack | active | confirmed | I10 | S — Synthetic modern diagnosis; no claim about her real blood pressure. |
| Absence of the uterus after an emergency hysterectomy at about 35, during a long, grave illness after the loss of a pregnancy; whether the ovaries were removed is not known; counted as a possible early menopause when weighing her cardiovascular risk | active | provisional | Z90.710 | S — Synthetic modern status linked to the retrospective account of a hysterectomy in 1941 or 1942; the operation itself rests on one secondary source. |
| Breathlessness from ticagrelor: a common, harmless side effect, resolved after the change to clopidogrel | resolved | confirmed | T45.525A | S — Synthetic diagnosis at the second visit; resolved at the third visit after the switch. |
| Raised lipoprotein(a), 172 nmol/L, an inherited risk-enhancing factor | active | confirmed | E78.41 | S — Synthetic result measured once at the second visit. |
| Financial strain: heavy debts after the loss of her home and estate, with income only from performing, which she has stopped while she recovers | active | confirmed | Z59.86 | S — Synthetic social need anchored to her documented debts and the loss of Les Milandes. |
| Anterior nosebleed from the left side of the nose, lasting about 25 minutes, in dry weather on aspirin and clopidogrel; stopped with pressure; no further bleeding | resolved | confirmed | R04.0 | S — Synthetic intercurrent problem at an unscheduled visit; it follows from dual antiplatelet therapy and does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (seated, average of two readings; home readings) | Every visit | Completed today | 122/76 mmHg; home average 122/74 |
| Examination | Weight, BMI and physical activity | Every visit | Completed today | 60.4 kg; rehabilitation completed; practicing up to an hour a day |
| Medication safety | Adherence: aspirin and P2Y12 inhibitor through the dual antiplatelet window, high-intensity statin, beta-blocker, ACE inhibitor | Every visit | Completed today | No missed doses |
| Medication safety | Bleeding on dual antiplatelet therapy (symptoms, hemoglobin when indicated) | Every visit | Completed today | One anterior nosebleed five weeks ago, managed without stopping antiplatelets (hemoglobin 11.9 g/dL then); none since |
| Laboratory | Lipid panel | Four to eight weeks after a statin start or change, then every three to twelve months | Completed today | About four months on atorvastatin 80 mg: LDL 62 mg/dL (58% fall from 146), total cholesterol 128, HDL 54, triglycerides 72; ALT 22 U/L. This is the first panel since the check due four to eight weeks after the start was missed; LDL is at goal, so the delay caused no harm and no change in treatment was postponed |
| Laboratory | Metabolic panel (potassium, creatinine, eGFR) on an ACE inhibitor | One to two weeks after a start or dose change, then every six to twelve months | Up to date | Potassium 4.7, creatinine 0.88 mg/dL eight weeks ago; next at about six months |
| Survey | Depression screen (PHQ-2, then PHQ-9) | After the infarction and periodically | Completed today | PHQ-9 3, from 7; item 9 scored 0 |
| Survey | Angina status (Seattle Angina Questionnaire-7) | At intake and every few months in the first year | Completed today | 94 |
| Examination | Stress testing or repeat angiography | Not for routine surveillance; for exercise prescription or new symptoms | Completed today | Exercise test today to prescribe exercise and guide the return to performing: about 10 METs, no angina or ischemic change |
| Imaging | Echocardiogram for left ventricular function | After the infarction if not done or if function was reduced; then only with clinical change | Not indicated | No clinical change |
| Referral | Cardiac rehabilitation | Within weeks of the infarction; 36 sessions | Completed today | All 36 sessions completed |
| Self-management | Self-management: chest-pain action plan, nitroglycerin, women's warning symptoms | Every visit | Completed today | Action plan reviewed for the dressing room and travel |
| Medication safety | Medicine and visit costs | Every visit | Completed today | Medicines affordable as generics; repayment plan in place |
Goal progress:
Guideline basis: 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025); Depression and Coronary Heart Disease: Recommendations for Screening, Referral, and Treatment: A Science Advisory From the American Heart Association (2008); CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026)
Follow-up: Preventive visit in about eight weeks. Seven-month review in about three months with a metabolic panel and a blood count. Call 911 for chest pain not relieved five minutes after one nitroglycerin. Next scheduled visit 1969-09-15: periodic adult preventive visit. [S]